TherapeuticsMD
TXMD
44 hedge funds and large institutions have $8.1M invested in TherapeuticsMD in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 8 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
2% more capital invested
Capital invested by funds: $7.94M → $8.1M (+$163K)
2.28% less ownership
Funds ownership: 33.96% → 31.68% (-2.3%)
10% less funds holding
Funds holding: 49 → 44 (-5)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$275K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.7K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$31.1K |
| 4 |
HF
HRT Financial
New York
|
+$30.4K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$849K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$43.8K |
| 3 |
CCA
Cygnus Capital Advisors
Atlanta,
Georgia
|
-$18K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$12.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.2K |
TXMD Hedge Fund Activity: Q2 2026 in Review
44 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q2 2026, worth a combined $8.1M — up 2.1% from $7.94M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TXMD and 4 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $275K. The largest seller was Squadron Capital Management, exiting entirely with an estimated $849K sold.
- 44 institutional investors held TherapeuticsMD (TXMD) as of Q2 2026, down from 49 in Q1 2026.
- Funds reported $8.1M of TherapeuticsMD stock for Q2 2026, up 2.1% quarter-over-quarter.
- 4 funds opened new TherapeuticsMD positions in Q2 2026 and 8 closed out, a net change of -4 holders.
- The largest TherapeuticsMD buyer in Q2 2026 was ADAR1 Capital Management, an estimated $275K added.
- The largest TherapeuticsMD seller in Q2 2026 was Squadron Capital Management, an estimated $849K sold.
Based on aggregated 13F filings for Q2 2026.